CSPC Pharmaceutical Group Limited Share Price and Company Fundamentals
Last traded: Today at 3:59 AM
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
Key Metrics
PE ratio
19.26
PB ratio
2.24
Dividend yield
3.90%
Beta
0.80
Market cap
$85.65B
Enterprise value
$79.48B
Company profile
| Industry / Sector | Drug Manufacturers - General / Healthcare |
|---|---|
| Full time employees | 19700 |
| Website | https://www.cspc.com.hk |
| Mailing address | No.896 Zhongshandong Street Gaoxin District Shijiazhuang 050035 China |
| Phone / Fax | 86 311 8703 7015 / 86 311 8703 9608 |
Dividends
Dividend yield
3.90%
Dividend amount
$0.30
Payout ratio
64.75%
5Y Avg. yield
-%
CSPC Pharmaceutical Group Limited paid $0.30 dividend and the ex-dividend date was 24 Jun 2026.The dividend payout ratio is 64.75%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.1093 dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of May 2026, following are the company executives and directors listed on CSPC Pharmaceutical Group Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Dongchen Cai | Executive Chairman | 71 | |
| Dr. Lei Cai | CEO & Vice Chairman of the Board | 45 | |
| Mr. Qingjie Wei | COO & Vice-Chairman of the Board | 55 | |
| Dr. Chunlei Li | Executive Director & Chief Scientist | 49 | |
| Mr. Huaiyu Wang | Executive Director | 62 | |
| Mr. Zhenguo Wang | Executive Director | 55 | |
| Mr. Cuilong Zhang | Executive Director | 56 | |
| Dr. Bing Yao | Executive Director | 48 | |
| Mr. Xin Cai | Executive Director | 33 | |
| Mr. Weiping Chen | Executive Director | 45 |
Profitability and management effectiveness
Profit margin
14.93%
Operating margin
8.42%
Return on assets
5.44%
Return on equity
11.33%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of CSPC Pharmaceutical Group Limited is 85.65B and its enterprise value is 79.48B. The enterprise value to revenue ratio of 1093 is 3.06. The enterprise value to EBITDA ratio of 1093 is 15.55.
The 1093's stocks Beta value is 0.80 making it 20% less volatile compared to HKEX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
CSPC Pharmaceutical Group Limited (HKEX:1093) Frequently Asked Questions
1. What is CSPC Pharmaceutical Group Limited's Stock Symbol?
CSPC Pharmaceutical Group Limited trades on HKEX under the ticker symbol "1093".
2. What is CSPC Pharmaceutical Group Limited's stock price today?
One share of 1093 stock can currently be purchased for approximately $7.51.
3. How can I contact CSPC Pharmaceutical Group Limited?
CSPC Pharmaceutical Group Limited's mailing address is No.896 Zhongshandong Street Gaoxin District Shijiazhuang 050035 China. The company can be reached via phone at 86 311 8703 7015.
4. What is CSPC Pharmaceutical Group Limited's official website?
The official website of CSPC Pharmaceutical Group Limited is https://www.cspc.com.hk.